

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2019PLC081123

Regd. Office: Alembic Road, Vadodra - 390 002

Tel: 0265-9837308

Email: apl.investors@alembic.co.inWebsite: www.alembicpharmaceuticals.com**Extract of Statement of Consolidated Unaudited Financial Results for the quarter and nine months period ended 31st December, 2023**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.12.2023	31.12.2022	31.03.2023
	(Unaudited)	(Unaudited)	(Audited)
Total Income from Operations	1,838.57	1,508.02	5,652.92
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary Items)	184.58	154.48	354.59
Net Profit for the period before tax (after Exceptional and/ or Extraordinary Items)	184.58	154.48	354.59
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary Items)	158.45	121.92	341.59
Total Comprehensive Income for the period	181.49	124.24	358.36
Equity Share Capital	38.31	38.31	38.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	8.78	6.25	17.40
Research and Development Expenses	114.48	156.89	721.84

Notes:

1.	Standard details	Quarter Ended		Year Ended
		31.12.2023	31.12.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Audited)
	Income from Operations	1,888.29	1,370.21	5,146.80
	Profit before Tax	258.70	144.31	346.58
	Profit After Tax	233.24	119.13	346.73
	Research and Development Expenses	113.75	149.62	689.39

2. The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.nseindia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited

541

Chirayz Amin

Chairman and CEO

Place : Vadodra

Date : 5th February, 2024